Orthocell (ASX:OCC) signed eight additional US distributors for its nerve repair product Remplir, lifting its total to 12, according to a Friday filing with the Australian bourse.
The company is preparing for the first product use in the US market while also planning EU and UK regulatory filings within the next year, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.